Global Scleroderma Treatment Market 2017-2021

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

• Market outline
• Scleroderma disease overview
• Market landscape
• Market overview
• Five forces analysis

PART 05: Pipeline landscape

PART 06: Market segmentation by drug class

• Anti-inflammatory drugs
• Immunosuppressants
• Others
• PDE5 inhibitors
• Calcium channel blockers

PART 07: Geographical segmentation

• Scleroderma treatment market in Americas
• Scleroderma treatment market in EMEA
• Scleroderma treatment market in APAC

PART 08: Decision framework

PART 09: Drivers and challenges

• Market drivers
• Market challenges

PART 10: Market trends

• Partnerships and strategic alliances
• Introduction of stem cells in scleroderma treatment
• Advent of novel therapies

PART 11: Vendor landscape

• Competitive scenario

PART 12: Key vendor analysis

• AstraZeneca
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Pfizer
• Other prominent vendors

PART 13: Appendix

• List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

• Manufacturers and suppliers
• Channel partners
• Industry experts
• Strategic decision makers

Secondary sources

• Industry journals and periodicals
• Government data
• Financial reports of key industry players
• Historical data
• Press releases

DATA ANALYSIS

Data Synthesis

• Collation of data
• Estimation of key figures
• Analysis of derived insights

Data Validation

• Triangulation with data models
• Reference against proprietary databases
• Corroboration with industry experts

REPORT WRITING